Pyrilutamide (KX-826) is a chemical developed by Kintor Pharmaceutical for the treatment of androgenetic alopecia. It is currently in Phase II clinical trials in China and the US. The purity of pyrilutamide used in PyriPure is >99%, confirmed by a professional testing lab.
Kintor Pharmaceutical is a clinical stage biotechnology company focused on discovering small molecule therapeutics targeting cancer and other androgen receptor related diseases. For drug-specific PTSR and LoA data, buy our Pyrilutamide PTSR & LoA Report.
What is Pyrilutamide?
Buy pyrilutamide Europe is a new treatment for hair loss that has shown promise in early clinical trials. It is a topical antiandrogen that works by blocking androgen receptors in the hair follicle. It is being developed by Kintor Pharmaceuticals, a company that focuses on androgen receptor-related diseases with unmet needs like hair loss and acne vulgaris. The drug is currently in phase 2 clinical trials for androgenic alopecia.
The phase 2 trial will be randomized, double-blinded, and vehicle-controlled. It will measure the change in non-vellus target area hair count after 6 months of treatment.
The raw material pyrilutamide (aka KX-826) used in PyriPure is >99% pure and is tested by a 3rd party to ensure its purity prior to usage. The solution is made from pure pyrilutamide powder and ethanol in a propylene glycol vehicle. The solution should be kept in a dark and cool place, such as a refrigerator. The solution is stable for up to one year after shipping.
Where can I buy Pyrilutamide?
Pyrilutamide (KX-826) is a new chemical developed by Kintor Pharmaceutical, a clinical stage drug company based in Suzhou, China. The company is focused on discovering and developing small molecule therapeutics targeting cancer and other androgen receptor related diseases. In particular, the company is working on a number of compounds designed to target DHT, which is thought to be responsible for hair loss in men and women.
KX-826 is currently in phase II clinical trials for androgenic alopecia. The trial will be conducted in China and is expected to complete in 2022. Kintor is also testing Buy pyrilutamide in Europe for use in prostate, breast, and liver cancer as well as for other conditions such as alopecia.
GlobalData’s Pyrilutamide LoA Report provides a comprehensive view of the drug and its clinical development status by tracking attributes such as Phase Transition and Likelihood of Approval (PTSR) scores, and indication benchmarks based on 18 years of historical data. For more information, purchase the report here.
What is the cost of Pyrilutamide?
Pyrilutamide (development code KX-826) is the strongest topical androgen receptor antagonist in development. It is being manufactured by Kintor Pharmaceutical as a treatment for androgenetic alopecia. The company has announced that phase 2 trials in the US and China are nearing completion.
These results will determine whether or not pyrilutamide can be safely and effectively used in both men and women to treat androgenetic alopecia. They will also provide an idea of how effective it might be compared to the current gold standard, finasteride.
GlobalData has a detailed report on this drug called the Pyrilutamide LoA Report which includes a comprehensive analysis of all the attributes that drive its success, as well as indication benchmarks based off of 18 years of historical data. You can purchase this report by clicking here.
How is Pyrilutamide prescribed?
Pyrilutamide works by blocking the combination of DHT and AR to slow down hair follicle growth. It also acts directly on the follicles to block the synthesis of testosterone. It is absorbed through the skin and then degraded in the blood stream. It is therefore very safe to use topically. It is also unlikely to cause unwanted side effects such as decreased libido or erectile dysfunction.
The drug is currently undergoing phase III clinical trials for androgenetic alopecia. This randomized, double-blind, vehicle controlled trial will observe a change in non-vellus target area hair count after 6 months of treatment. The trial is being conducted in China by Kintor Pharmaceuticals.
Kintor Pharmaceutical is a biotechnology company focused on developing treatments for androgen receptor-related diseases that do not have effective therapies. The company’s lead products include proxalutamide, pyrilutamide, and Destorsertib. Kintor Pharmaceuticals has extensive research and development operations in the United States and China. The company also has significant manufacturing capabilities for its small molecule products.